<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03815032</url>
  </required_header>
  <id_info>
    <org_study_id>18.238</org_study_id>
    <nct_id>NCT03815032</nct_id>
  </id_info>
  <brief_title>Assessing the Accuracy of the OptoWire DeuxTM in a Wire to Wire Comparison</brief_title>
  <acronym>ACCURACY</acronym>
  <official_title>Assessing the Accuracy of the OptoWire DeuxTM in a Wire to Wire Comparison</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Opsens Medical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the ACCURACY study is to assess the differences, if any, in FFR measurements made
      by the OptoWire Deux FFR guidewire by comparison of simultaneous data of two different
      OptoWire DeuxTM guidewires (group 1). In addition, the investigators will compare (group 2)
      the FFR measurements obtained from an OptoWire Deux FFR guidewire and compare it to the FFR
      measurement by a VERRATA-TM guidewire to assess coronary stenosis in the routine clinical
      practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, prospective, non-blinded clinical investigation enrolling
      consecutive patients with coronary lesion candidate for FFR assessment. The study aim to
      assess the differences, if any, in FFR measurements made by the OptoWire Deux FFR guidewire
      by comparison of simultaneous data of two different OptoWire DeuxTM guidewires (group 1,
      n=30). In addition, The investigators will compare (group 2, n=15) the FFR measurements
      obtained from an OptoWire Deux FFR guidewire and compare it to the FFR measurement by a
      VERRATA-TM guidewire to assess coronary stenosis in the routine clinical practice. The
      clinical investigation will be conducted in the Centre Hospitalier de l'Université de
      Montréal (CHUM). No clinical follow-up is requested after the end of the procedure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Actual">March 31, 2020</completion_date>
  <primary_completion_date type="Actual">January 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>delta FFR</measure>
    <time_frame>Day 1</time_frame>
    <description>To assess the magnitude of reading delta from wire to wire in a percutaneous coronary intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drift recording</measure>
    <time_frame>Day 1</time_frame>
    <description>The rate of significant drift, defined as Pd/Pa &lt;0.97 or &gt;1.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delta from guidewire to guidewire</measure>
    <time_frame>Day 1</time_frame>
    <description>Assess the magnitude of reading delta from guidewire to guidewire prior to equalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stents</measure>
    <time_frame>Day 1</time_frame>
    <description>The number of stents used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stents on FFR wire</measure>
    <time_frame>Day 1</time_frame>
    <description>The number of stents placed over an OptoWire DeuxTM guidewire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Workhorse guidewire</measure>
    <time_frame>Day 1</time_frame>
    <description>Number of Workhorse guidewire used.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Stenosis</condition>
  <condition>Atherosclerosis</condition>
  <condition>Atherosclerosis, Coronary</condition>
  <condition>Angina, Stable</condition>
  <condition>Angina, Unstable</condition>
  <condition>NSTEMI - Non-ST Segment Elevation MI</condition>
  <arm_group>
    <arm_group_label>Optowire Deux FFR assessment (1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A total of 45 consecutive patients will be recruited:
group 1 (n=30): To assess the differences in FFR measurements (drift) made by the OptoWire Deux FFRTM guidewire by comparison of simultaneous data of two different OptoWire DeuxTM guidewires</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optowire Deux FFR assessment (2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>group 2 (n=15): To assess the differences in FFR measurements (drift) obtained from an OptoWire DeuxTM FFR guidewire and compare it to the FFR measurement by a VERRATATM guidewire</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drift assessment of OptoWire Deux FFR wire (1)</intervention_name>
    <description>Simultaneous data of two different OptoWire DeuxTM guidewires (group 1) to assess a single coronary stenosis and detect any difference if any.</description>
    <arm_group_label>Optowire Deux FFR assessment (1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drift assessment of OptoWire Deux FFR wire (2)</intervention_name>
    <description>Simultaneous data of one Optowire Deux TM guide wires and one VERRATA-TM FFR wire (group 2) to assess a single coronary stenosis and detect any difference if any.</description>
    <arm_group_label>Optowire Deux FFR assessment (2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Single de novo coronary lesion or in-stent restenosis lesion with an operator assessed
             reference diameter ≥2.0 mm requiring FFR measurement based on the operator's clinical
             judgment

        Exclusion Criteria:

          -  Patients with ST-segment-elevation myocardial infarction (STEMI), culprit lesion of
             non-ST-segment-elevation myocardial infarction (NSTEMI), New York Heart Association
             class IV heart failure, suspected or visible thrombus, dissection or excessive
             calcification or tortuosity in the target vessel, or a stenosis in a bypass graft will
             be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samer Mansour, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier de l'Université de Montréal (CHUM)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X0C1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Pothineni NV, Shah NN, Rochlani Y, Nairooz R, Raina S, Leesar MA, Uretsky BF, Hakeem A. U.S. Trends in Inpatient Utilization of Fractional Flow Reserve and Percutaneous Coronary Intervention. J Am Coll Cardiol. 2016 Feb 16;67(6):732-733. doi: 10.1016/j.jacc.2015.11.042.</citation>
    <PMID>26868697</PMID>
  </reference>
  <results_reference>
    <citation>Fearon WF. Percutaneous coronary intervention should be guided by fractional flow reserve measurement. Circulation. 2014 May 6;129(18):1860-70. doi: 10.1161/CIRCULATIONAHA.113.004300.</citation>
    <PMID>24799502</PMID>
  </results_reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 7, 2019</study_first_submitted>
  <study_first_submitted_qc>January 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 24, 2019</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

